Search

Your search keyword '"Lebbe, Celeste"' showing total 643 results

Search Constraints

Start Over You searched for: Author "Lebbe, Celeste" Remove constraint Author: "Lebbe, Celeste"
643 results on '"Lebbe, Celeste"'

Search Results

1. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

2. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

3. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

4. Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline – update 2024

5. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma

6. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024

7. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024

8. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma

10. When to stop immunotherapy for advanced melanoma: the emulated target trials

11. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

12. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

15. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.

16. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

17. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

18. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

19. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

20. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023

21. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023

23. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

26. Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease

28. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort

29. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review

30. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors

31. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

32. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases

34. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022

35. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

36. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

38. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort

39. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib

40. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis

42. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

43. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

44. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

45. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response

46. Hematological immune related adverse events after treatment with immune checkpoint inhibitors

50. Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

Catalog

Books, media, physical & digital resources